EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

ImmunoGen, Inc. - Product Pipeline Review - 2015

  • ID: 3422649
  • Company Profile
  • August 2015
  • 42 pages
  • Global Markets Direct
1 of 3
ImmunoGen, Inc. - Product Pipeline Review - 2015

Summary

The report ‘ImmunoGen, Inc. - Product Pipeline Review - 2015’, provides an overview of the ImmunoGen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmunoGen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ImmunoGen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ImmunoGen, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ImmunoGen, Inc.’s pipeline products

Reasons to buy

- Evaluate ImmunoGen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ImmunoGen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ImmunoGen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ImmunoGen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ImmunoGen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ImmunoGen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

ImmunoGen, Inc. Snapshot

ImmunoGen, Inc. Overview

Key Information

Key Facts

ImmunoGen, Inc. - Research and Development Overview

Key Therapeutic Areas

ImmunoGen, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

ImmunoGen, Inc. - Pipeline Products Glance

ImmunoGen, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

ImmunoGen, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

ImmunoGen, Inc. - Drug Profiles

coltuximab ravtansine

Product Description

Mechanism of Action

R&D Progress

IMGN-529

Product Description

Mechanism of Action

R&D Progress

mirvetuximab soravtansine

Product Description

Mechanism of Action

R&D Progress

huHER3-8

Product Description

Mechanism of Action

R&D Progress

IMGN-289

Product Description

Mechanism of Action

R&D Progress

IMGN-779

Product Description

Mechanism of Action

R&D Progress

ImmunoGen, Inc. - Pipeline Analysis

ImmunoGen, Inc. - Pipeline Products by Target

ImmunoGen, Inc. - Pipeline Products by Route of Administration

ImmunoGen, Inc. - Pipeline Products by Molecule Type

ImmunoGen, Inc. - Pipeline Products by Mechanism of Action

ImmunoGen, Inc. - Recent Pipeline Updates

ImmunoGen, Inc. - Dormant Projects

ImmunoGen, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AVE-1642

AVE-9633

cantuzumab ravtansine

coltuximab ravtansine

IMGN-388

lorvotuzumab mertansine

Oncolysin B

ImmunoGen, Inc. - Company Statement

ImmunoGen, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

ImmunoGen, Inc., Key Information

ImmunoGen, Inc., Key Facts

ImmunoGen, Inc. - Pipeline by Indication, 2015

ImmunoGen, Inc. - Pipeline by Stage of Development, 2015

ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2015

ImmunoGen, Inc. - Partnered Products in Pipeline, 2015

ImmunoGen, Inc. - Partnered Products/ Combination Treatment Modalities, 2015

ImmunoGen, Inc. - Phase II, 2015

ImmunoGen, Inc. - Phase I, 2015

ImmunoGen, Inc. - Preclinical, 2015

ImmunoGen, Inc. - Pipeline by Target, 2015

ImmunoGen, Inc. - Pipeline by Route of Administration, 2015

ImmunoGen, Inc. - Pipeline by Molecule Type, 2015

ImmunoGen, Inc. - Pipeline Products by Mechanism of Action, 2015

ImmunoGen, Inc. - Recent Pipeline Updates, 2015

ImmunoGen, Inc. - Dormant Developmental Projects,2015

ImmunoGen, Inc. - Discontinued Pipeline Products, 2015

ImmunoGen, Inc., Subsidiaries

List of Figures

ImmunoGen, Inc. - Pipeline by Top 10 Indication, 2015

ImmunoGen, Inc. - Pipeline by Stage of Development, 2015

ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2015

ImmunoGen, Inc. - Partnered Products in Pipeline, 2015

ImmunoGen, Inc. - Pipeline by Top 10 Target, 2015

ImmunoGen, Inc. - Pipeline by Top 10 Route of Administration, 2015

ImmunoGen, Inc. - Pipeline by Top 10 Molecule Type, 2015

ImmunoGen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown
Adroll
adroll